Effect of an oral contraceptive containing drospirenone on the renin-angiotensin-aldosterone system in healthy female volunteers

Gynecological Endocrinology

Volumn 14, Issue 3, 2000, Pages 204-213

  Oelkers, W ^a   Helmerhorst, F M ^b   Wuttke, W ^d   Heithecker, R ^c  

^a FREIE UNIVERSITÄT BERLIN   (Germany)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^c BAYER PHARMA AG   (Germany)

^d Endokrinologie und Nephrologie ^*

Author keywords

Body weight; Drospirenone; Natural progesterone; Oral contraceptive; Renin angiotensin aldosterone system

Indexed keywords

ALDOSTERONE; DESOGESTREL; DESOGESTREL PLUS ETHINYLESTRADIOL; DROSPIRENONE; DROSPIRENONE PLUS ETHINYLESTRADIOL; ETHINYLESTRADIOL; ORAL CONTRACEPTIVE AGENT; RENIN; UNCLASSIFIED DRUG;

ADULT; ALDOSTERONE BLOOD LEVEL; ARTICLE; BLOOD PRESSURE; BODY WEIGHT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN EXPERIMENT; MULTICENTER STUDY; NORMAL HUMAN; PLASMA RENIN ACTIVITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM;

EID: 0033923167     PISSN: 09513590     EISSN: None     Source Type: Journal    
DOI: 10.3109/09513590009167683     Document Type: Article

References (14)

1. 1. Oelkers W, Berger V, Bolik A, Bahr V, Hazard B, Beier S, Elger W, Heithecker R. Dihydrospirorenone, a new progestogen with antimineralocorticoid activity: effects on ovulation, electrolyte excretion, and the renin-aldosterone system in normal women. J Clin Endocrinol Metab 1991;73:837-42
2. 2. Pollow K, Jucham N, Elger W, Jacobi N, Hoffmann G, Hobus V. Dihydrospirorenone (ZK30595): a novel synthetic progestagen - characterization of binding to different receptor proteins. Contraception 1992;46:561-74
3. 3. Losert W, Casals-Stenzel J, Buse M. Progestagens with antimineralocorticoid activity. Drug Res 1985;35:459-71
4. 4. Muhn P, Krattenmacher R, Beier S, Elger W, Schillinger E. Drospirenone: a novel progestogen with antimineralocorticoid and antiandrogenic activity. Contraception 1995;51:99-110
5. 5. Fuhrmann U, Krattenmacher R, Slater EP, Fritzmeier K-H. The novel progestin drospirenone and its natural counterpart progesterone: biochemical profile and antiandrogenic potential. Contraception 1996;54:243-51
6. 6. Oddens BJ. Women's satisfaction with birth control: a population survey of physical and psychological effects of oral contraceptives, intrauterine devices, condoms, natural family planning, and sterilization among 1466 women. Contraception 1999;59:277-86
7. 7. Rosenberg MJ, Waugh MS. Oral contraceptive discontinuation: a prospective evaluation of frequency and reasons. Am J Obstet Gynecol 1998;179:577-82
8. 8. Oelkers W, Foidart JM, Dombrovicz M, Welter A, Heithecker R. Effects of a new oral contraceptive containing an antimineralocorticoid progestogen, drospirenone, on the renin-aldosterone system, body weight, blood pressure, glucose tolerance and lipid metabolism. J Clin Endocrinol Metab 1995;80:1816-21
9. 9. Blümel A, Oelkers W. Measurement of human plasma renin substrate concentration by angiotensin I radioimmunoassay: a discussion of methodological problems. Z Klin Chem Biochem 1974;12:453-8
10. 10. Oelkers W, Schöneshöfer M, Blümel A. Effect of progesterone and four synthetic progestagens on sodium balance and the renin-aldosterone system in man. J Clin Endocrinol Metab 1974;39:882-90
11. 11. Oelkers W, Kleiner S, Bähr V. Effects of incremental infusions of atrial natriuretic factor on aldosterone, renin and blood pressure in humans. Hypertension 1988;12:462-7
12. 12. Walters WAW, Lim YL. Haemodynamic changes in women taking oral contraceptives. J Obstet Gynaecol Br Commonw 1970;77:1008-12
13. 13. Crane MG, Harris JJ. Effect of estrogens and gestagens on exchangeable sodium. In Fregly MJ, Fregly MS, eds. Oral Contraceptives and High Blood Pressure. Gainesville: Dolphin Press, 1974:159-69
14. 14. Oelkers W. Effects of estrogens and progestogens on the renin-aldosterone system and blood pressure. Steroids 1996;61:166-71